Why Some Newly Diagnosed Myeloma Patients Don’t Reach a Deep Response |Jonathan Kaufman, MD | скачать в хорошем качестве

Why Some Newly Diagnosed Myeloma Patients Don’t Reach a Deep Response |Jonathan Kaufman, MD |

Jonathan Kaufman, MD, shares the findings from a study characterizing newly diagnosed multiple myeloma (NDMM) patients treated with the combination daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd) who fail to achieve a very good partial response (VGPR) or experience early disease progression. If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286... For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.